Akkermansia bacteria plus infliximab for Crohn's healing
Treatments studied
Part of Digestive system clinical trials.
This study tests whether adding a special gut bacteria (Akkermansia muciniphila) to the standard biologic treatment infliximab can help heal the lining of the intestine better than infliximab alone. It is for people with active Crohn's disease who have not used biologics or antibiotics recently.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with Crohn's disease.
- Your Crohn's is currently active and causing moderate to severe symptoms.
- You have not used a biologic drug (like infliximab) or antibiotics or probiotics in the past 4–8 weeks.
- You have never had surgery to remove part of your intestine for Crohn's.
- You are willing to have up to 3 colonoscopies during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two drugs, infliximab and azathioprine, to see if it works better than either drug alone for children with moderate to severe Crohn's disease. The trial is for children who have not used these drugs before.
This trial tests whether adding a natural fatty acid (palmitoleic acid) to the standard biologic drug infliximab can help heal the gut lining in people with moderate to severe Crohn's disease. If you have active Crohn's and haven't had intestinal surgery or used biologics recently, you may qualify.
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
This trial uses a computer model to study how the body processes infliximab (a medicine that reduces inflammation) in people with Crohn's disease or ulcerative colitis. It aims to find the best dose to help control symptoms.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
Hear when a new Crohn's Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.